RNA-Targeting Lends Renewed Focus to Gene Therapy Development Efforts


Locanabio CEO James Burns, PhD, shares his outlook on the quickly changing landscape of gene therapy research.

No one can deny the lightning speed at which the gene and cell therapy space is advancing on a daily basis, but the ongoing evolution is particularly sweet for long-time industry players like James Burns, PhD, chief executive officer of Locanabio, Inc., a clinical-stage company focused on RNA-targeting gene therapies.

Locanabio recently presented new data at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, including an RNA-targeting CRISPR/Cas13d gene therapy approach for skipping USH2A exon 13 for the treatment of retinal disease, as well as preclinical in vivo data demonstrating safety and efficacy of their novel PUF RNA-binding protein system delivered via an adeno-associated virus serotype 9 (AAV9) vector in eliminating toxic CUG repeats in a mouse model of myotonic dystrophy type 1.

In an interview with GeneTherapyLive, Burns commented on the changing landscape of gene therapy research, adding a poignant reminder of why the field continues to push forward.

Related Videos
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
© 2024 MJH Life Sciences

All rights reserved.